What’s inside
View ResearchDiscover an intranasal stringent response vaccine targeting dendritic cells for tuberculosis therapy. This novel approach enhances the efficacy of standard treatment by inducing robust Th1 and Th17 immune responses. The fusion of the relMtb gene with the chemokine MIP-3α/CCL20 and intranasal delivery significantly improves mycobactericidal activity, reducing lung bacterial burden in a murine model of chronic TB. The study suggests this vaccination strategy as a promising adjunctive therapy for TB.
Intranasal Vaccine for TB Treatment
Novel intranasal DNA vaccine targeting dendritic cells for tuberculosis therapy.
Enhancing TB Therapy with DNA Vaccines
Study explores how DNA vaccines can enhance the efficacy of tuberculosis treatments.
Immunogenicity of MIP-3α/relMtb Fusion Vaccine
Analysis of immune responses triggered by MIP-3α/relMtb fusion vaccine for TB.
Combined Vaccination Strategies for TB
Investigating the combined use of MIP-3α fusion and intranasal routes for TB vaccines.
Robust T-cell Responses in TB Vaccination
Study shows intranasal vaccination induces strong Th1 and Th17 responses against TB.
Optimized TB Vaccination Strategies
Combining MIP-3α fusion and intranasal delivery enhances TB vaccine efficacy.
.svg)
.jpg)
.webp)
